ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dTpa vaccine

Its studies are mostly in Diphtheria, led by GlaxoSmithKline.

Furthest: phase 3, since May 13, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 3since May 13, 2026May 13, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2026First study: phase 3 study in Diphtheria-Tetanus-acellular Pertussis VaccinesFirst studyNCT07596173 · 90 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“dTpa vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596173Diphtheria-Tetanus-acellular Pertussis Vaccines · Japan3CompletedSep 4, 202690

How it is read

Names in the registry

  • “dTpa vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.